These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30221150)

  • 1. Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.
    Motoya S; Watanabe M; Wallace K; Lazar A; Nishimura Y; Ozawa M; Thakkar R; Robinson AM; Singh RSP; Mostafa NM; Suzuki Y; Hibi T
    Inflamm Intest Dis; 2018 Jul; 2(4):228-235. PubMed ID: 30221150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.
    Sandborn WJ; Colombel JF; Schreiber S; Plevy SE; Pollack PF; Robinson AM; Chao J; Mulani P
    Inflamm Bowel Dis; 2011 Jan; 17(1):141-51. PubMed ID: 20848500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.
    Chen B; Gao X; Zhong J; Ren J; Zhu X; Liu Z; Wu K; Kalabic J; Yu Z; Huang B; Kwatra N; Doan T; Robinson AM; Chen MH
    Therap Adv Gastroenterol; 2020; 13():1756284820938960. PubMed ID: 32733600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.
    Dubinsky MC; Rosh J; Faubion WA; Kierkus J; Ruemmele F; Hyams JS; Eichner S; Li Y; Huang B; Mostafa NM; Lazar A; Thakkar RB
    Inflamm Bowel Dis; 2016 Apr; 22(4):886-93. PubMed ID: 26950307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
    Van Steenbergen S; Bian S; Vermeire S; Van Assche G; Gils A; Ferrante M
    Aliment Pharmacol Ther; 2017 Apr; 45(7):923-932. PubMed ID: 28164321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
    Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
    Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease.
    Wu KC; Ran ZH; Gao X; Chen M; Zhong J; Sheng JQ; Kamm MA; Travis S; Wallace K; Mostafa NM; Shapiro M; Li Y; Thakkar RB; Robinson AM
    Intest Res; 2016 Apr; 14(2):152-63. PubMed ID: 27175116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab for induction of remission in Crohn's disease.
    Abbass M; Cepek J; Parker CE; Nguyen TM; MacDonald JK; Feagan BG; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.
    Wolf D; D'Haens G; Sandborn WJ; Colombel JF; Van Assche G; Robinson AM; Lazar A; Zhou Q; Petersson J; Thakkar RB
    Aliment Pharmacol Ther; 2014 Sep; 40(5):486-97. PubMed ID: 25041859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
    Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
    Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
    Viola F; Civitelli F; Di Nardo G; Barbato MB; Borrelli O; Oliva S; Conte F; Cucchiara S
    Am J Gastroenterol; 2009 Oct; 104(10):2566-71. PubMed ID: 19550415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L; Laclotte C; Bigard MA
    Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn's disease.
    Chen L; Lu Z; Kang D; Feng Z; Li G; Sun M; Liu Z; Wu W; Fang L
    Front Pharmacol; 2022; 13():913720. PubMed ID: 36034848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.